medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Número 1

Siguiente >>

Rev Invest Clin 2005; 57 (1)


Actitud ante los inhibidores selectivos de COX-2

Zaragoza JL

Idioma: Español
Referencias bibliográficas: 34
Paginas: 6-12
Archivo PDF: 121.56 Kb.


FRAGMENTO

Los inhibidores selectivos de ciclooxigenasa-2 (COX-2) o coxibs como una nueva clase de antiinflamatorios no esteroideos (AINES) se introdujeron en el mercado a partir de 1999 y desde entonces se han comercializado para uso clínico: celecoxib, etoricoxib, lumiracoxib, parecoxib y rofecoxib.
Su mecanismo de acción se basa en la inhibición selectiva y eficiente de conversión del ácido araquidónico a prostaglandina H2 por la COX-2, la cual se sobreexpresa en tejidos inflamados, sin inhibir los efectos citoprotectores y fisiológicos de la COX-1 en la mucosa gástrica y otros órganos. Los estudios de equivalencia han demostrado que para el control de la analgesia e inflamación son equiparables a las dosis terapéuticas de naproxeno, diclofenaco e ibuprofeno, sin embargo, se les reconoce una menor toxicidad gástrica. Y ésta ha sido el principal estímulo para la investigación, el uso clínico y la mercadotecnia que durante estos años ha constituido una esperanza en relación con los AINES no selectivos. Sin embargo, el futuro promisorio, ofrecido por estos inhibidores selectivos ha terminado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hawkey CJ COX-2 inhibitors. Lancet 1999; 353(9149): 307-13.

  2. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345(6): 433-42.

  3. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59(4): 957-80. Erratum in: Drugs 2001; 61(4): 498.

  4. Ormrod D, Wellington K, Wagstaff AJ. Valdecoxib. Drugs. 2002; 62(14): 2059-71; discussion 2072-3.

  5. Debashis S. Merck withdraws arthritis drug worldwide. BMJ 2004; 329: 816.

  6. Pedros C, Cereza G, Laporte JR. First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs. Med Clin (Barc) 2002; 118(11): 415-17.

  7. Hankey GJ, Eikelboom JW. Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not? Stroke 2003; 34(11): 2736-40.

  8. Croofford LJ, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxigenase-2 inhibitors: a report of four cases. Arthritis Rheum 2000; 43: 1891-6.

  9. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin PUBLISHED ON LINE http://www.pnas.org/cgi/content/abstract/98/25/14583. Accessibility verified February 21, 2005.

  10. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 43(21): 1520-8.

  11. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et. al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS Study: A randomized controlled trial celecoxib long-term arthritis safety study. JAMA 2000; 284(10): 1247-55.

  12. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001; 175: 214-17.

  13. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8): 954-9.

  14. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular Events Associated with rofecoxib in a colorectal adenoma chemoprevention trial published on line at www.nejm.org February 15, 2005 (10.1056/NEJMoa050493). Accessibility verified February 21, 2005.

  15. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364(9435): 675-84.

  16. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery Published on line at www.nejm.org February 15, 2005 (10.1056/NEJMoa050330). Accessibility verified February 21, 2005.

  17. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068-73.

  18. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92(4): 411-18.

  19. Solomon SD, McMurray JV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M for the Adenoma Prevention with Celecoxib (APC) Study Investigators Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention Published on line at www.nejm.org February 15, 2005 (10.1056/NEJMoa050405) . Accessibility verified February 21, 2005.

  20. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365(9458): 475-81.

  21. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327(7407): 128.

  22. Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology 2002; 58(7): 1050-4.

  23. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Alzheimer’s Disease Cooperative Study. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289(21): 2819-26.

  24. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies BMJ 2003; 327(7407): 128.

  25. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003; 146(4): 591-604.

  26. Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL. Adverse Drug Events Involving COX-2 Inhibitors. Ann Pharmacother 2003; 37(9): 1203-13.

  27. Freedman GM, Kreitzer JM, Badola Ruchi. Rofecoxib-associated upper gastrointestinal bleed: a case report. Mt Sin J Med 2002; 106.

  28. Bing RJ. Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events? Curr Atheroscler Rep 2003; 5(2): 114-17.

  29. Papaioannides D, Bouropoulos C, Sinapides D, Korantzopoulos P, Akritidis N. Acute renal dysfunction associated with selective COX-2 inhibitor therapy. Int Urol Nephrol 2001; 33(4): 609-11.

  30. Kaur C, Sarkar R, Kanwar AJ. Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides. Dermatology 2001; 203(4): 351.

  31. Gagnon R, Julien M, Gold P. Selective celecoxib-associated anaphylactoid reaction. J Allergy Clin Immunol 2003; 111(6): 1404-5.

  32. Ashwath ML, Katner HP. Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib. Postgrad Med J 2003; 79(931): 295-6.

  33. Coulter DM, Clark DW, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 2003; 327: 1214-15.

  34. Nies AS. Principles of therapeutics. In: Goodman and Gilman. The pharmacological basis of therapeutics. 10th edit. USA: McGraw-Hill, 2001, p. 63.




2020     |     www.medigraphic.com